论文部分内容阅读
基因技术公司(Genentech)的抗癌药Avastin(bevacizumab)有可能引起罕见的、可逆的后继性白质脑病综合征(reversibleposterior leucoencephalopathy syndrome,RPLS)。这一潜在的不良反应于2006年3月由新英格兰医学杂志首先披露。为此,基因技术公司对用药者进行了一项完整的安全
Genentech’s anticancer drug Avastin (bevacizumab) is likely to cause a rare, reversible reversible posterior leucoencephalopathy syndrome (RPLS). This potential adverse reaction was first disclosed by the New England Journal of Medicine in March 2006. For this reason, GeneTech has a complete safety package for its users